Pharmacological management of challenging behavior of individuals with intellectual disability

Research in Developmental Disabilities

Volumn 25, Issue 6, 2004, Pages 523-537

  McGillivray, Jane A ^a   McCabe, Marita P ^a  

^a DEAKIN UNIVERSITY   (Australia)

Author keywords

Age; Challenging behavior; Gender; Intellectual disability; Pharmacological management

Indexed keywords

ANTIANDROGEN; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIMIGRAINE AGENT; ANXIOLYTIC AGENT; BENZATROPINE MESILATE; CARBAMAZEPINE; CHLORPROMAZINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLONAZEPAM; DIAZEPAM; HALOPERIDOL; HYPNOTIC SEDATIVE AGENT; LITHIUM; METHYLPHENIDATE; NEUROLEPTIC AGENT; OLANZAPINE; PSYCHOSTIMULANT AGENT; PSYCHOTROPIC AGENT; RISPERIDONE; SEDATIVE AGENT; SERTRALINE; THIORIDAZINE; VALPROIC ACID;

ADULT; AGED; ARTICLE; BEHAVIOR; FEMALE; HUMAN; INTELLECTUAL IMPAIRMENT; MAJOR CLINICAL STUDY; MALE; SIDE EFFECT;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; BEHAVIOR CONTROL; DRUG THERAPY, COMBINATION; DRUG UTILIZATION; FEMALE; HUMANS; MALE; MENTAL DISORDERS; MENTAL RETARDATION; MIDDLE AGED; VICTORIA;

EID: 8444230204     PISSN: 08914222     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ridd.2004.03.001     Document Type: Article

References (63)

1. Aman, M. G. (1984). Drugs and learning in mentally retarded persons. In G. D. Burrows & J. S. Werry (Eds.), Advances in human psychopharmacology (vol. 3, pp. 121-163). Greenwich, CT: JAI Press.
2. Aman M.G., Sarphare G., Burrow W.H. Psychotropic drugs in group homes: Prevalence and relation to demographic/psychiatric variables. American Journal on Mental Retardation. 99:1995;500-509
3. Aman, M., & Singh, N. (1991). Pharmacological intervention. In J. Matson & J. Mulick (Eds.), Handbook of mental retardation (2nd ed., pp.347-372). New York: Pergamon Press.
4. Astbury, J., & Cabral, M. (2000). Women's mental health: An evidence based review. Geneva: World Health Organization.
5. Baumeister, A. A., Sevin, J. A., & King, B. H. (1998). Neuroleptic medications. In S. Reiss & M. G. Aman (Eds.), Psychotropic medications and developmental disabilities: The international consensus handbook (pp. 133-150). Columbus OH: Ohio State University.
6. Bender A.D. Pharmacodynamic principles of drug therapy in the aged. Journal of the American Geriatric Society. 22:1974;296-308
7. Borthick-Duffy S.A. Epidemiology and prevalence of psychopathology in people with mental retardation. Journal of Consulting and Clinical Psychology. 62:1994;17-27
8. Boshes R.A. Pharmacotherapy for patients with mental retardation and mental illness. Psychiatric Annals. 17:1987;627-632
9. Branford D. A review of antipsychotic drugs prescribed for people with learning disabilities who live in Leicestershire. Journal of Intellectual Disability Research. 40:1996;358-368
10. Brylewski J., Duggan L. Antipsychotic medication for challenging behaviour in people with intellectual disability: A systematic review of randomized controlled trials. Journal of Intellectual Disability Research. 43:1999;360-371
11. Callacott R.A., Cooper S.A., Branford D., McGrother C. Epidemiology of self injurious behaviour in adults with learning disabilities. British Journal of Psychiatry. 173:1998;428-432
12. Connor D.F., Posever T.A. A brief review of atypical neuroleptics in individuals with developmental disorders. Mental Health Aspects of Developmental Disabilities. 4:1998;93-102
13. Cooper S.A. Epidemiology of psychiatric disorders in elderly compared with younger adults with learning disabilities. British Journal of Psychiatry. 170:1997a;375-380
14. Cooper S.A. High prevalence of dementia among people with learning disabilities not attributable to Down's Syndrome. Psychological Medicine. 27:1997b;609-616
15. Cooper S.A. A population-based health survey of maladaptive behaviour associated with dementia in elderly people with learning disabilities. Journal of Intellectual Disability Research. 41:1997c;481-487
16. Cooper, S. A. (1999). Psychiatric disorders in elderly people with developmental disabilities. In N. Bouras (Ed.), Psychiatric and behavioural disorders in developmental disabilities and mental retardation (pp. 212-225). New York: Cambridge University Press.
17. Cooper S.A., Prasher V.P. Maladaptive behaviours and symptoms of dementia in adults with Down's syndrome compared with adults with intellectual disability of other aetiologies. Journal of Intellectual Disability Research. 42:1998;293-300
18. Craig T.J., Bracken J. An epidemiologic study of p.r.n./stat. medication use in a state psychiatric hospital. Annals of Clinical Psychiatry. 7:1995;57-64
19. Crews W.D., Bonaventura S., Rowe F. Dual diagnosis: Prevalence of psychiatric disorders in a large state residential facility for individuals with mental retardation. American Journal on Mental Retardation. 98:1994;724-731
20. Davidson P.W., Cain N.N., Sloane-Reeves J.E., Van-Speybroech A., Segel J., Gutkin J., et al. Characteristics of community-based individuals with mental retardation and aggressive behavioral disorders. American Journal on Mental Retardation. 98:1994;704-716
21. Deb S., Thomas M., Bright C. Mental disorder in adults with intellectual disability. 2. The rate of behaviour disorders among a community-based population aged between 16 and 64 years. Journal of Intellectual Disability Research. 45:2001;506-514
22. Didden R., Duker R., Korzilius H. Meta-analytic study on treatment effectiveness for problem behaviours with individuals who have mental retardation. American Journal of Mental Retardation. 101:1997;387-399
23. Dudley J.R., Ahlgrim-Delzell L., Calhoun M.L. Diverse diagnostic and behavioural patterns amongst people with dual diagnosis. Journal of Intellectual Disability Research. 43:1999;70-79
24. Emerson, E. (2001). Challenging behaviour: Analysis and intervention in people with severe intellectual disabilities (2nd ed.). Cambridge: Cambridge University Press.
25. Emerson, E., Alborz, A., Reeves, D., Mason, H., Swarbrick, R., Kiernan, C., et al. (1997). The HARC challenging behaviour project. Report 2. The prevalence of challenging behaviour. Manchester: Hester Adrian Research Centre, University of Manchester.
26. Emerson, E., Kiernan, C., Alborz, A., Reeves, D., Hatton, C., Mason, H., et al. (1997). The HARC Challenging Behaviour Project: Summary report. Manchester: Hester Adrian Research Centre, University of Manchester.
27. Emerson, E., Moss, S. C., & Kiernan, C. K. (1999). The relationship between challenging behaviour and psychiatric disorders in people with severe intellectual disabilities. In N. Bouras (Ed.), Psychiatric and behavioural disorders in developmental disabilities and mental retardation (pp. 38-48). Cambridge: Cambridge University Press.
28. Emerson E., Robertson N., Gregory C., Hatton C., Kessissoglou S., Hallam A., et al. Treatment and management of challenging behaviours in residential settings. Journal of Applied Research in Intellectual Disabilities. 13:2000;197-215
29. Fleming I., Caine A., Ahmed S., Smith S. Aspects of the use of psychoactive medication among people with intellectual disabilities who have been resettled from long-stay hospitals into dispersed housing. Journal of Applied Research in Intellectual Disabilities. 9:1996;194-205
30. Friedlander M.B., Lazar S., Klancnik J. Atypical antipsychotic use in treating adolescents and young adults with developmental disabilities. Canadian Journal of Psychiatry. 46:2001;741-745
31. Harper D.C., Wadsworth J.S. Behavioral problems and medication utilization. Mental Retardation. 31:1993;97-103
32. Intellectually Disabled Persons Services Act (1986). Act No. 53/1986. Melbourne: Victoria Government Printer.
33. Intellectual Disability Review Panel (1989). Annual report of the IDRP for the year ending June 1989. Melbourne: Author.
34. Intellectual Disability Review Panel (2001). Annual report of the IDRP for the year ending June 2001. Melbourne: Author.
35. Janicki M.P., Dalton A.J., Henderson C.M., Davidson P.W. Mortality and morbidity among older adults with intellectual disability: Health services considerations. Disability and Rehabilitation. 21:1999;284-294
36. Jauernig R., Hudson A. Evaluation of an interdisciplinary review committee managing the use of psychotropic medication with people with intellectual disabilities. Australia and New Zealand Journal of Developmental Disabilities. 20:1995;51-61
37. Jenkins R., Rose J., Jones T. The checklist of challenging behavior and its relationship with the Psychopathology Inventory for Mentally Retarded Adults. Journal of Intellectual Disability Research. 42:1998;273-278
38. Joyce T., Ditchfield H., Harris P. Challenging behaviour in community services. Journal of Intellectual Disability Research. 45:2001;130-138
39. Kalachnik, J. E., Levethal, B. L., James, D. H., Sovner, R., Kastner, T. A., Walsh, K., et al. (1998). Guilelines for the use of pschotropic medication. In S. Reiss & M. G. Aman (Eds.), Psychotropic medication and developmental disabilities: The international consensus handbook (pp. 45-71). Columbus, Ohio: Ohio State University.
40. Kiernan C., Reeves D., Alborz A. The use of anti-psychotic drugs with adults with learning disabilities and challenging behaviour. Journal of Intellectual Disability Research. 39:1995;247-263
41. Kirman B. Drug therapy in mental handicap. British Journal of Psychiatry. 127:1975;545-549
42. Lunsky Y. Depressive symptoms in intellectual disability: Does gender play a role? Journal of Intellectual Disability Research. 47:2003;417-427
43. Matson J.L., Bamburg J.W., Mayville E.A., Pinkston J., Bielecki J., Kuhn D., et al. Psychopharmacology and mental retardation: A 10 year review (1990-1999). Research in Developmental Disabilities. 21:2000;263-296
44. Matson J.L., Bielecki J., Mayville S.B., Matson M.L. Psychopharmacology research for individuals with mental retardation: Methodological issues and suggestions. Research in Developmental Disabilities. 24:2003;149-157
45. McClintock K., Hall S., Oliver C. Risk markers associated with challenging behaviours in people with intellectual disabilities: A meta-analytic study. Journal of Intellectual Disability Research. 47:2003;405-416
46. MIMS Annual (2001). 23rd ed. Australia: MIMS Australia.
47. Molyneux P., Emerson E., Caine A. Prescription of psychotropic medication to people with intellectual disabilities in primary health care settings. Journal of Applied Research in Intellectual Disabilities. 12:1999;46-57
48. Pary R. Psychoactive drugs used with adults and elderly adults who have mental retardation. American Journal on Mental Retardation. 98:1993;121-127
49. Quereshi, H. (1993). Prevalence of challenging behavior. In I. Flemming & B. S. Kroese (Eds.), People with learning disability and severe challenging behavior: New developments in service and therapy (pp. 11-42). Manchester: University Press.
50. Reiss S., Aman M.G. The international consensus process on psychopharmacology and intellectual disability. Journal of Intellectual Disability Research. 41:1997;448-455
51. Reiss, S., & Aman, M. G. (Eds.). (1998). Psychotropic medications and developmental disabilities: The international consensus handbook. Columbus, Ohio: The Ohio State University Nisonger Center.
52. Rinck C., Calkins C.F. Patterns of psychotropic medication use among older persons with developmental disabilities. Journal of Applied Gerontology. 8:1989;216-227
53. Rinck C., Guidry J., Calkins C.F. Review of states' practices on the use of psychotropic medication. American Journal on Mental Retardation. 93:1989;657-668
54. Robertson J., Emerson E., Gregory N., Hatton C., Kessissoglou S., Hallam A. Receipt of psychotropic medication by people with intellectual disabilities in residential settings. Journal of Intellectual Disability Research. 44:2000;666-676
55. Ryan M. Drug use in N.S.W. institutions - Innovation for inertia. Australian and New Zealand Journal of Developmental Disabilities. 17:1991;177-181
56. Sachdev P. Psychoactive drug use in an institution for intellectually handicapped persons. Medical Journal of Australia. 155:1991;75-79
57. Sommi, R. W., Benefield, W. H., Curtis, J. L., Lott, R. S., Saklad, J. J., & Wilson, J. (1998). Drug interactions with psychotropic medications. In S. Reiss & M. G. Aman (Eds.), Psychotropic medication and developmental disabilities: The international consensus handbook (pp. 115-131). Columbus, Ohio: Ohio State University.
58. Sturmey P. Diagnositic-based pharmacological treatment of behavior disorders in persons with developmental disabilities: A review and a decision-making typology. Research in Developmental Disabilities. 16:1995;235-252
59. Suresh T. 'As required' neuroleptics: Have these drugs a place in the management of challenging behaviours in intellectual disability? Journal of Intellectual Disability Research. 42:1998;500-504
60. Thorpe L., Davidson P., Janicki M. Healthy ageing - Adults with intellectual disabilities: Biobehavioural issues. Journal of Applied Research in Intellectual Disabilities. 14:2001;218-228
61. Tollefson G., Beasley M., Tamura R., Tran P., Potvin J. Blind controlled long term study of the comparative incidence of treatment emergent tardive dyskinesia with olanzapine or haloperidol. American Journal of Psychiatry. 154:1997;1248-1253
62. Tu J.B. A survey of psychotropic medication in mental retardation facilities. Journal of Clinical Psychiatry. 40:1979;125-128
63. Wressel S., Tyrer S., Berney T. Reduction in antipsychotic drug dosage in mentally handicapped patients. British Journal of Psychiatry. 157:1990;101-106